 |
|
|
| |
Efficacy and Safety of Simtuzumab for the Treatment of NASH with Bridging Fibrosis or Cirrhosis: Results of Two Phase 2b, Dose-Ranging, Randomized, Placebo-Controlled Trials
|
| |
| |
Reported by Jules Levin
EASL 2017 April 19-23 Amsterdam Netherlands
Arun J. Sanyal,1 Manal F. Abdelmalek,2 Anna Mae Diehl,2 Stephen Caldwell,3 Mitchell L. Shiffman,4 Reem Ghalib,5 Eric Lawitz,6 Don C. Rockey,7 Raul Aguilar Schall,8 Catherine Jia,8 Bryan J. McColgan,8 Robert P. Myers,8 G. Mani Subramanian,8 John G. McHutchison,8 Andrew J. Muir,2 Vlad Ratziu,9 Nezam H. Afdhal10, Zachary Goodman,11 Jaime Bosch,12 Stephen A. Harrison13
1Virginia Commonwealth University, Richmond, VA, USA; 2Duke Clinical Research Institute, Durham, NC, USA; 3University of Virginia, Charlottesville, VA, USA; 4Liver Institute of Virginia, Richmond, VA, USA; 5Texas Clinical Research Institute, Arlington, TX, USA; 6Texas Liver Institute, University of Texas Health, San Antonio, TX, USA; 7Medical University of South Carolina, Charleston, SC, USA; 8Gilead Sciences, Inc., Foster City, CA, USA; 9Hopital Pitie-Salpetriere, Paris, France; 10Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA; 11Inova Fairfax Hospital, Falls Church, VA, USA; 12University of Barcelona, Barcelona, Spain; 13Pinnacle Clinical Research, San Antonio, Texas, USA
|
| |
|
|
|
|
|
